Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy. II. Effects of core heteroatoms and meso-substituents on biological activity

Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2002, Pages 449-461

  Hilmey, David G ^a   Abe, Masako ^a   Nelen, Marina I ^a   Stilts, Corey E ^a   Baker, Gary A ^a   Baker, Sheila N ^a   Bright, Frank V ^a   Davies, Sherry R ^b   Gollnick, Sandra O ^b   Oseroff, Allan R ^b   Gibson, Scott L ^c   Hilf, Russell ^c   Detty, Michael R ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 BIS(1 PHENYL 1 PYRROLOMETHYL)SELENOPHENE; 2,5 BIS(1 PHENYL 1 PYRROLOMETHYL)THIOPHENE; 2,5 BIS[(4 FLUOROPHENYL)HYDROXYMETHYL]SELENOPHENE; 2,5 BIS[(4 FLUOROPHENYL)HYDROXYMETHYL]THIOPHENE; 2,5 BIS[(4 METHOXYPHENYL)HYDROXYMETHYL]THIOPHENE; 2,5 BIS[(4 N,N DIMETHYLAMINOPHENYL)HYDROXYMETHYL]THIOPHENE; 2,5 BIS[(4 TOLYL)HYDROXYMETHYL]THIOPHENE; 2,5 BIS[(4 TRIFLUOROMETHYLPHENYL)HYDROXYMETHYL]THIOPHENE; 2,5 BIS[1 (4 FLUOROPHENYL 1 PYRROLOMETHYL)]THIOPHENE; 2,5 BIS[1 (4 METHOXYPHENYL 1 PYRROLOMETHYL)]THIOPHENE; 5,10 BIS 4 (N,N DIMETHYLAMINO)PHENYL 15,20 DIPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 (TRIFLUOROMETHYL)PHENYL 15,20 DIPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 BIS 4 HYDROXYPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 BIS 4 METHOXYPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 BIS(4 ETHYL PHENOXYACETATE) 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 BIS(4 PHENOXYACETIC ACID) 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 DIPHENYL 21 SELENA 23 THIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 DIPHENYL 21 THIA 23 SELENAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 DIPHENYL 21 THIAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 DIPHENYL 21,23 DISELENAPORPHYRIN; 5,10 BIS 4 FLUOROPHENYL 15,20 DIPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 METHOXYPHENYL 15,20 DIPHENYL 21,23 DITHIAPORPHYRIN; 5,10 BIS 4 TOLYL 15,20 DIPHENYL 21,23 DITHIAPORPHYRIN; 5,10 DIPHENYL 15,20 BIS (4 ETHYL PHENOXYACETATE) 21,23 DITHIAPORPHYRIN; 5,10 DIPHENYL 15,20 BIS (4 PHENOXYACETIC ACID) 21,23 DITHIAPORPHYRIN; 5,10 DIPHENYL 15,20 BIS 4 HYDROXYPHENYL 21,23 DITHIAPORPHYRIN; 5,10,15,20 TETRAPHENYL 21 THIAPORPHYRIN; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ARTICLE; CELL KILLING; CHEMICAL MODIFICATION; CRYSTALLIZATION; DEMETHYLATION; DIASTEREOISOMER; DRUG SOLUBILITY; DRUG SYNTHESIS; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; POLYMERIZATION; SAPONIFICATION; SKIN ABSORPTION;

ANIMALS; CARBOXYLIC ACIDS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORESCENCE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RATS; SOLUBILITY; SPECTROPHOTOMETRY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS; TUMOR CELLS, CULTURED; WATER;

EID: 0037122781     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0103662     Document Type: Article

References (39)

1. Photodynamic therapy
2. How does photodynamic therapy work?
3. Photodynamic therapy for lung cancer - A review of 19 years' experience
4. Photodynamic therapy of bronchial cancers
5. Photodynamic therapy of gastrointestinal tumors: A review
6. Photodynamic therapy of malignant glioma. A review of literature
7. Evaluating the role of photodynamic therapy in the management of pancreatic cancer
8. Photodynamic therapeutics: Basic principles and clinical applications
9. A preliminary pharmacokinetic study of intravenous photofrin in patients
10. Photodynamic therapy
11. Water-soluble, core-modified porphyrins as novel, longer-wavelength-absorbing sensitizers for photodynamic therapy
12. Photochemical treatment with the lysosomally localized dye tetra(4-sulfonatophenyl)porphine results in lysosomal release of the dye but not of β-N-Acetyl-D-glucosamidase activity
13. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine
14. Biodistribution of photosensitizing agents
15. In vivo fluorescence of phthalocyanines during light exposure
16. Experimental porphyric neuropathy: A preliminary report
17. 4 and its relation to photodynamic therapy
18. Synthesis of tetraphenylporphyrin molecules containing heteroatoms other than nitrogen. Part 4. Symmetrically and unsymmetrically substituted tetraphenyl-21, 23-dithiaporphyrins
19. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen: II. Tetraphenyl-21-selena-23-thiaporphyrin and tetraphenyl-21, 23-diselenaporphyrin
20. Synthesis of new tetraphenylporphyrin molecules containing heteroatoms other than nitrogen. III. Tetraphenyl-21-tellura-23-thiaporphyrin: An internally-bridged porphyrin
21. Novel core-modified expanded porphyrins with meso-aryl substituents; synthesis, spectral and structural characterization
22. Five-coordinate complexes of 21-thiaporphyrin. The preparation, spectra, and structures of iron(II), nickel(II), and copper(II) complexes
23. Synthesis of 5,20-diphenyl-10, 15-bis(p-tolyl)-21-selenaporphyrin (SeDPDTPH)
24. 5,20-Bis(4-sulphophenyl)-10,15-bis(2-methoxy-4-sulfophenyl)-21-thiaporphyrin as a new potent sensitizer in photodynamic therapy
25. The new sensitizing agents for photodynamic therapy: 21-Selenaporphyrin and 21-thiaporphyrin
26. Porphyrin chemistry pertaining to the design of anti-cancer drugs; Part 2, the synthesis and in vitro tests of water-soluble porphyrins containing in the meso positions, the functional groups: 4-Methylpyridinium, 4-sulfonatophenyl, in combination with phenyl, 4-pyridyl, 4-nitrophenyl, or 4-aminophenyl
27. Water-soluble thiaporphyrins and metallothiaporphyrins: Synthesis, characterization, ground- and excited-state properties
28. In vivo fluorescence spectroscopy and imaging for oncological applications
29. Clinical pharmacokinetic studies of photofrin by fluorescence spectroscopy in the oral cavity, the esophagus, and the bronchi
30. Clinical imaging fluorescence apparatus for the endoscopic photodetection of early cancers by use of photofrin-II
31. Luminescence and structure of the protonated forms of meso-tetraarylporphyrins in solution
32. Mesoscopic structure of meso-tetrakis(4-sulfonatophenyl)porphine J-aggregates
33. Structural and photophysical properties of a water-soluble porphyrin associated with polycations in solution and electrostatically assembles ultrathin films
34. Chalcogenopyrylium dyes as potential photochemotherapeutic agents. III. Solution studies of heavy atome effects on triplet yields, quantum efficiencies of singlet oxygen generation, rates of reaction with singlet oxygen, and emission quantum yields
35. Quantum yields for the photosensitized formation of the lowest electronically excited singlet state of molecular oxygen in solution
36. Cutaneous porphyrin photosensitization: Murine ear swelling as a marker of the acute response
37. The time course of cutaneous porphyrin photosensitization of the murine ear
38. 2,4,6-Triarylchalcogenopyrylium dyes related in structure to the antitumor agent AA1 as in vitro sensitizers for the photodynamic therapy of cancer
39. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays